



Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Feb 22 2021, 7:30 AM EST

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy

Feb 12 2021, 11:36 AM EST

Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™

Feb 2 2021, 7:30 AM EST

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	199.95m
Last Price	\$2.08
52-Week	\$0.99 - \$3.79

03/04/2021 04:00 PM EST

Investor Relations

ir@abeonatherapeutics.com

Management Team

Michael Amoroso

Executive Vice President, Chief Operating Officer

Jay Bircher

Chief Technical Officer

Edward Carr

Chief Accounting Officer, Principal Financial Officer

Jodie Gillon, M.P.H.

Chief Patient Officer

Greg Gin

Vice President, Investor Relations and Corporate Communications

Scott Nogi

Vice President, Business Operations

Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.